Diego Rey

Diego is a co-founder, board member, and Chief Scientific Officer of Endpoint Health, a precision immunology therapeutics company. Prior to co-founding Endpoint Health, Diego invented the core technology and led investigational efforts related to Roche’s antibiotic therapy guidance research and development program. Prior to Roche, Diego co-founded GeneWEAVE, a company that developed rapid tests to detect and guide therapy choice for serious infections, which was acquired by Roche in 2015. After Roche, Diego was a Visiting Partner at Y Combinator which has a portfolio of over 3,000 companies with a combined value of over $400B and includes over 300 life sciences and healthcare companies. Diego received a BS in Electrical Engineering from UC Santa Barbara and an MS and PhD in Biomedical Engineering from Cornell University.